This reprogramming results in increased production of NADPH, serine, purine nucleotides, and glutathione, which collectively support the aggressive tumorigenesis of NRF2-activated cancer cells (Mitsuishi et al, 2012; DeNicola et al, 2015). The gene discussed is NFE2L2; the disease is cancer.